ERGO.US Entia Biosciences Inc
- Market cap
- USD 77.4K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is ERGO.US undervalued?
Graham numberThe Graham number of Entia Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Entia Biosciences Inc fundamental analysis
No fundamental analysis for Entia Biosciences Inc yet.
Entia Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Entia Biosciences Inc
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing …
Full company profileEntia Biosciences Inc financial statements
Entia Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 403K | 369K | 315K | 656K | 347K | 265K | - | - | - | - |
| Gross Profit | 271K | 262K | 184K | 411K | 216K | 174K | - | - | - | - |
| Operating Income | -1.47M | -1.08M | -2.68M | -1.77M | -1.92M | -1.17M | - | - | - | - |
| EBITDA | -1.37M | -980K | -2.92M | -1.92M | -2.08M | -1.29M | - | - | - | - |
| Net Income | -1.73M | -1.53M | -3.25M | -2.64M | -2.41M | -1.47M | - | - | - | - |
| EPS | -0.28 | -0.21 | -0.43 | -0.28 | -0.10 | -0.05 | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 405K | 463K | 631K | 871K | 449K | 439K | - | - | - | - |
| Total Liabilities | 665K | 1.11M | 1.58M | 987K | 1.24M | 2.41M | - | - | - | - |
| Shareholders' Equity | -260K | -648K | -950K | -117K | -791K | -1.97M | - | - | - | - |
| Cash & Short-term Investments | 16.6K | 13.1K | 36.9K | 99.5K | 24.1K | 76.1K | - | - | - | - |
| Total Debt | 333K | 456K | 423K | 418K | 279K | 1.05M | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -209K | -315K | -767K | -680K | -537K | -715K | - | - | - | - |
| Capital Expenditure | 44.0K | 63.3K | 64.6K | 45.5K | 21.3K | 7.12K | - | - | - | - |
| Free Cash Flow | -253K | -378K | -831K | -726K | -558K | -722K | - | - | - | - |
| Ratios | ||||||||||
| ROA | -427.0% | -329.8% | -514.9% | -302.8% | -537.1% | -335.4% | - | - | - | - |
| Net Profit Margin | -428.7% | -413.5% | -1,032.4% | -401.7% | -694.5% | -554.7% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Entia Biosciences Inc dividends
Entia Biosciences Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:10 on Feb 15, 2012.
Who owns Entia Biosciences Inc
Ownership data of Entia Biosciences Inc is not available yet.
Entia Biosciences Inc company profile
- Company name
- Entia Biosciences Inc
- Ticker
- ERGO.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 13565 SW Tualatin-Sherwood Road, Sherwood, OR, United States, 97140
- Phone
- 971-228-0709
- Website
- entiabio.com
About Entia Biosciences Inc
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.
Entia Biosciences Inc management
3- Dr. Marvin S. Hausman M.D.Chairman and Chief Science & Technology Officer · born 1941
- Mr. Timothy A. TimminsCEO & President · born 1957
- Mr. Elliot A. L. Shelton Esq.Secretary and Director · born 1950